Immucell (ICCC) Fundamental Analysis: Revenue, Earnings & Valuation

5.60 / 10

Netural

ICCC's fundamentals score 5.6/10, reflecting a mixed but not alarming status. Key positives include a healthy Cash-MV and Current assets turnover ratio, while weaknesses lie in the Fixed assets turnover ratio and Net profit / Total profit percentage. The company's 42.6% gross profit margin offers some buffer, yet the low fixed-asset efficiency and near-total profit reliance on net profit temper enthusiasm. Overall, the fundamental picture is modest but not catastrophic.

Analysis Checks(6/10)

Revenue-MV

Value-0.78

Score3/3

Weight36.58%

1M Return20.82%

Inventory turnover ratio

Value1.36

Score2/3

Weight-2.70%

1M Return-2.63%

Gross profit margin (%)

Value42.64

Score1/3

Weight-0.55%

1M Return-0.54%

Profit-MV

Value0.10

Score3/3

Weight22.70%

1M Return12.18%

PB-ROE

Value0.18

Score1/3

Weight9.82%

1M Return7.02%

Current assets turnover ratio

Value1.26

Score2/3

Weight1.24%

1M Return1.15%

Fixed assets turnover ratio

Value0.68

Score1/3

Weight-1.69%

1M Return-1.64%

Asset-MV

Value-0.50

Score2/3

Weight24.26%

1M Return15.13%

Cash-MV

Value-0.07

Score2/3

Weight10.65%

1M Return7.73%

Net profit / Total profit (%)

Value99.55

Score0/3

Weight-0.31%

1M Return-0.30%

Is ICCC fundamentally strong?

ICCC scores 5.60/10 on fundamentals and holds a Fair valuation at present. Backed by its 6.31% ROE, 8.37% net margin, 24.29 P/E ratio, 1.89 P/B ratio, and 157.14% earnings growth, these metrics solidify its Netural investment rating.